QPPV.COM KNOWLEDGE ASSESSMENT

Vilanterol: Discovery, Development, Safety and Pharmacovigilance โ€” Knowledge Assessment

Test your understanding of the concepts covered by Vilanterol: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A reaction appears in a product warning section but not in the adverse-reaction table. What is the most appropriate listedness approach?
Question 2 of 10 A patient taking a nonselective beta-blocker reports worsening bronchospasm after starting a vilanterol-containing inhaler. Which interpretation is most appropriate?
Question 3 of 10 A short dose-ranging trial finds improved trough FEV1 after once-daily vilanterol. What is the most defensible conclusion from this evidence alone?
Question 4 of 10 What is the most defensible interpretation of limited human pregnancy data and no direct human-milk measurements for vilanterol?
Question 5 of 10 A patient taking a strong CYP3A4 inhibitor reports increased palpitations after starting fluticasone furoate/vilanterol. What is the most appropriate pharmacovigilance interpretation?
Question 6 of 10 A clinician asks whether the EU paediatric authorisation for Relvar can be inferred from the US Breo label. What is the appropriate response?
Question 7 of 10 What is the principal rationale for combining umeclidinium with vilanterol in Anoro Ellipta?
Question 8 of 10 Why does beta2-receptor selectivity not make vilanterol entirely free of cardiovascular risk?
Question 9 of 10 In COPD studies, fluticasone furoate/vilanterol had lower exacerbation rates than vilanterol alone. Which interpretation best respects the comparison?
Question 10 of 10 What does the EMA conclusion removing certain umeclidinium/vilanterol products from additional monitoring after a specified study obligation most appropriately mean?

Select an answer to continue.

QPPV.com